|
Qnexa® is a once a day, proprietary, oral, controlled-release formulation of low dose phentermine and topiramate, which is believed to address both appetite and satiety - the two main mechanisms that impact eating behavior - in one capsule. Qnexa appears to induce significantly greater weight loss than either individual compound. Further, clinical trials conducted with Qnexa have demonstrated superior efficacy and a significantly improved safety profile as compared to either active agent alone or other currently available therapeutic options.
Phentermine has been available for treating obesity since the 1950s, and is still the most widely prescribed weight loss therapy. Topiramate was approved in 1996 for treating epilepsy, and more recently as a prophylactic for migraine. The rationale behind Qnexa is to expand topiramate’s therapeutic window by using a very low dose and combining it with phentermine, which acts via a different mechanism. Topiramate works via GABA and other agonist properties and increases satiety, while phentermine is noradrenergic and non-serotonergic, and reduces appetite.
More Info about Qnexa
| Drug Type: | Other |
| Current FDA Status: | Pending Decision |
| Current Drug Phase: | NDA |
|